1SXP logo

SCHOTT Pharma AG & Co. KGaA Stock Price

XTRA:1SXP Community·€3.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

1SXP Share Price Performance

€20.50
-4.65 (-18.49%)
€20.43
Fair Value
€20.50
-4.65 (-18.49%)
0.3% overvalued intrinsic discount
€20.43
Fair Value
Price €20.50
AnalystConsensusTarget €20.43
AnalystHighTarget €25.90
AnalystLowTarget €13.00

1SXP Community Narratives

·
Fair Value €20.43 0.3% overvalued intrinsic discount

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value €25.9 20.8% undervalued intrinsic discount

Aging Population And Biologics Growth Will Fuel Advanced Packaging

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value €13 57.7% overvalued intrinsic discount

Intensifying Climate Mandates And Protectionism Will Erode Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€13
57.7% overvalued intrinsic discount
Revenue
5.49% p.a.
Profit Margin
14.77%
Future PE
13.24x
Price in 2029
€15.49

Trending Discussion

No trending discussion available.

Updated Narratives

1SXP logo

1SXP: Lebanon Expansion And Confirmed 2026 Guidance Will Support Balanced Outlook

Fair Value: €20.43 0.3% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
1SXP logo

1SXP: Higher Discount Rate And Lower P/E Will Pressure Future Returns

Fair Value: €13 57.7% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
1SXP logo

1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares

Fair Value: €25.9 20.8% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and good value.

0 Risks
3 Rewards

SCHOTT Pharma AG & Co. KGaA Key Details

€991.2m

Revenue

€664.8m

Cost of Revenue

€326.5m

Gross Profit

€183.6m

Other Expenses

€142.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 12, 2026
0.95
32.94%
14.41%
23.7%
View Full Analysis

About 1SXP

Founded
1884
Employees
4839
CEO
Christian Mias
WebsiteView website
www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.